Neuraxis announces ib-stim results from a large, pediatric, multi-center registry

Carmel, ind., march 27, 2024 (globe newswire) -- neuraxis, inc. (“neuraxis,” or the “company”) (nyse american: nrxs), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced the results of a multicenter registry study on ib-stim for pediatric disorders of gut-brain interaction (dgbi). ib-stim is neuraxis' proprietary percutaneous electrical nerve field stimulation (penfs) technology therapy. the large and comprehensive study concluded efficacy of ib-stim for gastrointestinal symptoms and functionality for pediatric disorders of gut-brain interaction (dgbi).
NRXS Ratings Summary
NRXS Quant Ranking